Portugal news in English.

Subscribe

Infarmed Recalls Five Batches of the Hepatitis B Pill Entecavir Viatris Over a Contamination Risk at the Ingredient Stage

Two batches of the 0.5 mg tablets and three of the 1 mg tablets are recalled after a counterpart regulator found manufacturing problems with the active substance. The batch numbers, and why patients should not stop treatment on their own.

Infarmed Recalls Five Batches of the Hepatitis B Pill Entecavir Viatris Over a Contamination Risk at the Ingredient Stage
Blister packs of tablets (illustrative; not the recalled medicine). Photo: Tarasna0922, CC BY-SA 4.0, via Wikimedia Commons

Infarmed (Autoridade Nacional do Medicamento e Produtos de Saúde, the national medicines authority) on Thursday 19 November ordered the recall of five batches of Entecavir Viatris, an antiviral taken for chronic hepatitis B, and the immediate suspension of their distribution. According to Circular Informativa n.º 108/CD/550.20.001 (Information Circular 108), a counterpart regulator found nonconformities in the manufacture of the active substance "related to potential contamination and cross-contamination". The circular does not name that regulator or the country, and it says nothing about whether any patient has been harmed.

The batches recalled

  • Entecavir Viatris 0.5 mg film-coated tablets (registration number 5727979): batch 3231256, expiring December 2027, and batch 8213521, expiring August 2028.
  • Entecavir Viatris 1 mg film-coated tablets (registration number 5728019): batch 8199304, expiring December 2027; batch 8184740, expiring April 2027; and batch 3242972, expiring May 2028.

Anyone holding these batches in stock may not sell, dispense or administer them and must send them back, Infarmed says. The circular is addressed to hospitals, the regional health administrations, health centres, the professional orders and associations, and wholesale distributors. It gives no separate instruction to patients.

What the medicine is for

Entecavir Viatris is a generic entecavir authorised across the EU by the European Commission since September 2017; the marketing authorisation holder is Viatris Limited, in Ireland. According to its European Medicines Agency product information, it treats chronic hepatitis B virus infection in adults, including people whose liver is damaged, and in children from 2 to under 18 years of age.

If you take it

  • Check the batch. The batch number ("Lote" or "Lot") and the expiry date are printed on the box and on the blister strip. Compare them with the five numbers above.
  • Do not simply stop. The patient leaflet says: "Do not stop Entecavir Viatris without your doctor's advice", because some people get very serious hepatitis symptoms when they stop taking entecavir. If your pack is from one of the recalled batches, contact the doctor or the hospital pharmacy that supplies your treatment about a replacement before you run out.
  • Ask Infarmed. Its medicines information centre, the CIMI (Centro de Informação do Medicamento e dos Produtos de Saúde), answers on 21 798 7373 and at [email protected], and the Linha do Medicamento (Medicines Line) is on 800 222 444.

Infarmed last month gave hospitals notice that the Nolotil injection leaves the Portuguese market on 1 February 2027, also for manufacturing reasons.

Subscribe to The Portugal Brief

Portugal news in English, free by email. Choose your newsletters.

Already subscribed? Sign in